Bradner leaves a trimmer NIBR focused on platforms

Jay Bradner’s six-year tenure at the helm of Novartis’ discovery engine saw the pharma grow its footprint in platforms such as the physician-scientist’s home turf of targeted degradation and chemical biology, while trimming its early stage pipeline to prioritize assets with a first-mover advantage.  

On Thursday,  Novartis AG (SIX:NOVN; NYSE:NVS) announced Bradner will step down from its executive committee, and Fiona Marshall would assume the role of president of the Novartis Institutes for BioMedical Research (NIBR), effective Nov. 1. ...